this in vivo product candidates are late in stages of their clinical development, Phase III, with the company aiming for NTLA-2002 BLA submission by 2026 and its first commercial launch by 2027 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback